Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 8-K (Current Report)
Date of Report: April 26, 2021
Reporting Period: Event-based report regarding a specific regulatory submission on April 26, 2021.
Key Financial Metrics
This filing is a regulatory disclosure regarding a product submission and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes or operational results are reported in this document. The filing discloses a procedural update regarding the BD Alaris System.
Guidance, Outlook, and Management Commentary
- Regulatory Action: BD submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the BD Alaris System.
- Purpose of Submission: The submission aims to update regulatory clearance, implement new features, and address open recall issues.
- Technical Updates: The filing notes the introduction of a new software version for the BD Alaris System providing clinical, operational, and cybersecurity updates.
- Legal Disclaimer: The information is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into future filings.
Investor Verification Checklist
- Verify the status of the FDA 510(k) clearance for the BD Alaris System following this submission.
- Review the specific details of the "open recall issues" mentioned in the press release (Exhibit 99.1) to assess potential operational impact.
- Monitor for future filings regarding the approval timeline and implementation of the new cybersecurity and clinical software updates.